CCL2 and neoplasm: It is known that CCL2 secreted by tumor and stromal cells can recruit immune cells, including macrophages and peripheral leukocytes, to shape the tumor immune microenvironment (TIME) [10], a key factor determining the efficacy of ICB therapy [11].